Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets

详细信息    查看全文

• 作者：Senthilmurugan Ramalingam<sup>asup><sup> ; sup><sup>bsup> ; Vidya P. Ramamurthy<sup>asup><sup> ; sup><sup>bsup> ; Vincent C.O. Njar<sup>asup><sup> ; sup><sup>bsup><sup> ; sup><sup>csup><sup> ; sup><sup>vnjar@som.umaryland.edusup>
• 关键词：Prostate cancer ; Androgen ; Signaling pathways ; Castration resistant prostate cancer
• 刊名：The Journal of Steroid Biochemistry and Molecular Biology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：166
• 期：Complete
• 页码：16-27
• 全文大小：1319 K
• 卷排序：166

文摘

Androgen deprivation therapy (ADT) is treatment of choice for recurrent PCa. Patients eventually develop CRPC- a more advanced and resistant PCa phenotype. Host of molecular alterations are involved in acquiring resistance to ADT and CRPC. Array of drugs are precisely designed to target aberrant signaling pathways. Review summarizes key aberrant pathways in PCa and therapeutics influencing them.